

Diem Vuong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1030662/publications.pdf>

Version: 2024-02-01

24
papers

345
citations

933447

10
h-index

839539

18
g-index

25
all docs

25
docs citations

25
times ranked

569
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 4414-4425.	7.0	70
2	CT radiomics and PET radiomics: ready for clinical implementation?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 355-370.	0.7	58
3	Radiomic biomarkers for head and neck squamous cell carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 868-878.	2.0	28
4	FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients. <i>EJNMMI Research</i> , 2020, 10, 81.	2.5	27
5	Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients. <i>Medical Physics</i> , 2020, 47, 4045-4053.	3.0	23
6	Interchangeability of radiomic features between [18F]â€‹ ¹⁸ F FDG PET and [18F]â€‹ ¹⁸ F FDG PET/MR. <i>Medical Physics</i> , 2019, 46, 1677-1685.	3.0	22
7	Radiomics Feature Activation Maps as a New Tool for Signature Interpretability. <i>Frontiers in Oncology</i> , 2020, 10, 578895.	2.8	17
8	Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types. <i>British Journal of Radiology</i> , 2021, 94, 20200947.	2.2	16
9	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 636672.	2.8	15
10	Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 16, 109-112.	2.9	13
11	Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 22, 131-136.	2.9	12
12	Systematic Review on the Association of Radiomics with Tumor Biological Endpoints. <i>Cancers</i> , 2021, 13, 3015.	3.7	11
13	Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. <i>EJNMMI Research</i> , 2021, 11, 79.	2.5	11
14	Independent Monte-Carlo dose calculation for MLC based CyberKnife radiotherapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 015015.	3.0	6
15	Benchmarking Monte-Carlo dose calculation for MLC CyberKnife treatments. <i>Radiation Oncology</i> , 2019, 14, 172.	2.7	6
16	Computed-tomography-based radiomics features for staging of interstitial lung disease â€‹“ transferability from experimental to human lung fibrosis - a proof-of-concept study. , 2019, , .		4
17	Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. <i>Scientific Reports</i> , 2021, 11, 20890.	3.3	3
18	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. <i>Frontiers in Oncology</i> , 2022, 12, 830627.	2.8	2

#	ARTICLE	IF	CITATIONS
19	Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition.. Journal of Clinical Oncology, 2019, 37, 9575-9575.	1.6	1
20	EP-1480: Patient-specific QA for CyberKnife MLC plans using Monte Carlo. Radiotherapy and Oncology, 2017, 123, S791.	0.6	0
21	EP-1842: Benchmarking of Monte Carlo dose calculation for MLC based CyberKnife Radiotherapy. Radiotherapy and Oncology, 2018, 127, S994-S995.	0.6	0
22	76P Robustness of radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR. Journal of Thoracic Oncology, 2018, 13, S41.	1.1	0
23	THU0345â€¦TEXTURE-BASED RADIOMICS FEATURES DISCRIMINATE DIFFERENT STAGES OF EXPERIMENTAL INTERSTITIAL LUNG DISEASE. , 2019, , .		0
24	PO-1571: Radiomics for prediction of metastatic melanoma patient survival after immunotherapy. Radiotherapy and Oncology, 2020, 152, S851.	0.6	0